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Background
Self-amplifying RNAs (replicons) of positive-strand
viruses such as alphaviruses are potentially safe and use-
ful vectors for delivering vaccine antigens. We pre-
viously showed that recombinant alphavirus replicon
particles (VRP), used in prime-boost regimen with Env
in MF59 protein protected rhesus macaques against
mucosal challenge with SHIVSF162P4 (J. Virol. 84:5975,
2010).
Novartis recently developed a synthetic self-amplifying
mRNA (SAM™) vaccine platform, using cell-free RNA
production and non-viral vaccine delivery systems. The
SAM™ platform avoids the limitations of cell culture pro-
duction that complicate production of the alphavirus VRPs
and other viral vector systems. Safety concerns associated
with the potential generation of replication competent
virus (RCV) are eliminated, and the absence of viral struc-
tural proteins reduces issues associated with anti-vector
immunity, a major limitation of other vectored vaccine
systems.
Methods
HIV- SAM™ vaccines were evaluated in small animals
and nonhuman primates (NHP).
Results
Here we show that SAM™ vaccines encoding HIV anti-
gens induced potent systemic and mucosal immune
responses in small animals and nonhuman primates
(NHP). Humoral and cellular responses elicited in mice
with HIV-SAM™ vaccines were superior to naked DNA
or RNA and comparable to those seen with alphavirus
replicon particles (VRPs). Robust binding and neutralizing
antibodies were seen following two immunizations with a
HIV-SAM™ vaccine encoding subtype C TV1 gp140 in
rabbits. The same vaccine elicited both IFNg and IL2 T-cell
responses, B-cell ELISpots, and Env-specific antibody
responses in rhesus macaques, also after only two immuni-
zations. Importantly, the vaccines were well-tolerated with
no local or systemic adverse events observed.
Conclusion
These results provide the first evidence in a primate
species that vaccination with formulated self-amplifying
RNA is safe and immunogenic, eliciting robust immune
responses.
The safety, immunogenicity, and ease of production
provided by SAM™ vaccines provide a rationale for accel-
erated evaluations of this platform in the context of HIV
vaccines.
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